A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy

Biomaterials

Volumn 35, Issue 29, 2014, Pages 8450-8466

  Bao, Xiuli ^a   Wang, Wei ^a   Wang, Cheng ^a   Wang, Yu ^b   Zhou, Jianping ^a   Ding, Yang ^a   Wang, Xiaoyi ^a   Jin, Yuting ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II type 1 receptor targeting; Candesartan; Co delivery; Multifunctional copolymer anticancer conjugate; Tumor anti angiogenesis therapy; Wild type p53

Indexed keywords

CELL ENGINEERING; CHITOSAN; COPOLYMERS; DRUG THERAPY; ENDOTHELIAL CELLS; GENE EXPRESSION; GENE THERAPY; GRAFTING (CHEMICAL); MOLECULAR BIOLOGY; ONCOLOGY;

CANDESARTAN; CO DELIVERIES; MULTIFUNCTIONAL COPOLYMER-ANTICANCER CONJUGATE; RECEPTOR TARGETING; WILD TYPES;

TUMORS;

AMIDE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANTINEOPLASTIC AGENT; CHITOSAN GRAFT POLYETHYLENEIMINE CANDESARTAN; COPOLYMER; MESSENGER RNA; PLASMID DNA; POLYETHYLENEIMINE; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; CHITOSAN; CHITOSAN-GRAFT-POLYETHYLENIMINE; DNA; TETRAZOLE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CANCER THERAPY; CAPILLARY DENSITY; CELL MIGRATION; CHEMICAL BOND; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DEACETYLATION; DNA DRUG COMPLEX; DOWN REGULATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SYNTHESIS; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NANOFABRICATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; GENE THERAPY; GENE TRANSFER; GENETICS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; VASCULARIZATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; CELL LINE, TUMOR; CHITOSAN; DNA; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENES, P53; GENETIC THERAPY; HUMANS; MALE; MICE, INBRED BALB C; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLYETHYLENEIMINE; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES;

EID: 84904099817     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.06.025     Document Type: Article

References (48)

1. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972, 175:409-416.
2. Liang Y., Wu J., Stancel G.M., Hyder S.M. P53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. JSteroid Biochem Mol Biol 2005, 93:173-182.
3. Teodoro J.G., Parker A.E., Zhu X., Green M.R. P53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006, 313:968-971.
4. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., et al. Restoration of p53 function leads to tumour regression invivo. Nature 2007, 445:661-665.
5. Xu Q., Xia Y., Wang C.-H., Pack D.W. Monodisperse double-walled microspheres loaded with chitosan-p53 nanoparticles and doxorubicin for combined gene therapy and chemotherapy. JControl Release 2012, 163:130-135.
6. Goldstein I., Marcel V., Olivier M., Oren M., Rotter V., Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 2011, 18:2-11.
7. Yamakuchi M., Lotterman C.D., Bao C., Hruban R.H., Karim B., Mendell J.T., et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci U S A 2010, 107:6334-6339.
8. Zhang L., Yu D., Hu M., Xiong S., Lang A., Ellis L.M., et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000, 60:3655-3661.
9. Lu X., Wang Q.-Q., Xu F.-J., Tang G.-P., Yang W.-T. Acationic prodrug/therapeutic gene nanocomplex for the synergistic treatment of tumors. Biomaterials 2011, 32:4849-4856.
10. Xu Q., Leong J., Chua Q.Y., Chi Y.T., Chow P.K.-H., Pack D.W., et al. Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials 2013, 34:5149-5162.
11. Zhao F., Yin H., Li J. Supramolecular self-assembly forming a multifunctional synergistic system for targeted co-delivery of gene and drug. Biomaterials 2014, 35:1050-1062.
12. Ping Y., Liu C., Zhang Z., Liu K.L., Chen J., Li J. Chitosan- graft-(PEI-β-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery. Biomaterials 2011, 32:8328-8341.
13. Duceppe N., Tabrizian M. Factors influencing the transfection efficiency of ultra low molecular weight chitosan/hyaluronic acid nanoparticles. Biomaterials 2009, 30:2625-2631.
14. Mao S., Sun W., Kissel T. Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 2010, 62:12-27.
15. Moreira C., Oliveira H., Pires L., Simões S., Barbosa M., Pêgo A. Improving chitosan-mediated gene transfer by the introduction of intracellular buffering moieties into the chitosan backbone. Acta Biomater 2009, 5:2995-3006.
16. Jiang H.-L., Xu C.-X., Kim Y.-K., Arote R., Jere D., Lim H.-T., et al. The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway. Biomaterials 2009, 30:5844-5852.
17. Kim J.-H., Minai-Tehrani A., Kim Y.-K., Shin J.-Y., Hong S.-H., Kim H.-J., et al. Suppression of tumor growth in H-ras 12V liver cancer mice by delivery of programmed cell death protein 4 using galactosylated poly (ethylene glycol)-chitosan- graft-spermine. Biomaterials 2012, 33:1894-1902.
18. Chen X., Meng Q., Zhao Y., Liu M., Li D., Yang Y., et al. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett 2013, 328:318-324.
19. Egami K., Murohara T., Shimada T., K-i Sasaki, Shintani S., Sugaya T., et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. JClin Invest 2003, 112:67-75.
20. Deshayes F., Nahmias C. Angiotensin receptors: a new role in cancer?. Trends Endocrinol Metab 2005, 16:293-299.
21. Ino K., Shibata K., Kajiyama H., Nawa A., Nomura S., Kikkawa F. Manipulating the angiotensin system-new approaches to the treatment of solid tumours. Expert Opin Biol Ther 2006, 6:243-255.
22. Matsoukas M.-T., Cordomí A., Ríos S., Pardo L., Tselios T. Ligand binding determinants for angiotensin II type 1 receptor from computer simulations. JChem Inf Model 2013, 53:2874-2883.
23. Kim E., Yang J., Kim H.-O., An Y., Lim E.-K., Lee G., et al. Hyaluronic acid receptor-targetable imidazolized nanovectors for induction of gastric cancer cell death by RNA interference. Biomaterials 2013, 34:4327-4338.
24. Willis L., El-Remessy A., Somanath P., Deremer D., Fagan S. Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clin Sci 2011, 120:307-319.
25. Vold I., Christensen B.E. Periodate oxidation of chitosans with different chemical compositions. Carbohydr Res 2005, 340:679-684.
26. Park M.R., Han K.O., Han I.K., Cho M.H., Nah J.W., Choi Y.J., et al. Degradable polyethylenimine-alt-poly (ethylene glycol) copolymers as novel gene carriers. JControl Release 2005, 105:367-380.
27. Liu C., Liu F., Feng L., Li M., Zhang J., Zhang N. The targeted co-delivery of DNA and doxorubicin to tumor cells via multifunctional PEI-PEG based nanoparticles. Biomaterials 2013, 34:2547-2564.
28. Qian Y., Zha Y., Feng B., Pang Z., Zhang B., Sun X., et al. PEGylated poly (2-(dimethylamino) ethyl methacrylate)/DNA polyplex micelles decorated with phage-displayed TGN peptide for brain-targeted gene delivery. Biomaterials 2013, 34:2117-2129.
29. Wang Y., Liu P., Duan Y., Yin X., Wang Q., Liu X., et al. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer. Biomaterials 2014, 35:983-992.
30. Goyal R., Tripathi S.K., Tyagi S., Sharma A., Ram K.R., Chowdhuri D.K., et al. Linear PEI nanoparticles: efficient pDNA/siRNA carriers invitro and invivo. Nanomedicine 2012, 8:167-175.
31. Hatakeyama H., Akita H., Harashima H. Amultifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma. Adv Drug Deliv Rev 2011, 63:152-160.
32. T-i Kim, Rothmund T., Kissel T., Kim S.W. Bioreducible polymers with cell penetrating and endosome buffering functionality for gene delivery systems. JControl Release 2011, 152:110-119.
33. Köping-Höggård M., Vårum K., Issa M., Danielsen S., Christensen B., Stokke B., et al. Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers. Gene Ther 2004, 11:1441-1452.
34. Lee M., Nah J.-W., Kwon Y., Koh J.J., Ko K.S., Kim S.W. Water-soluble and low molecular weight chitosan-based plasmid DNA delivery. Pharm Res 2001, 18:427-431.
35. Yang Y., Aw J., Chen K., Liu F., Padmanabhan P., Hou Y., et al. Enzyme-responsive multifunctional magnetic nanoparticles for tumor intracellular drug delivery and imaging. Chem Asian J 2011, 6:1381-1389.
36. Wong K., Sun G., Zhang X., Dai H., Liu Y., He C., et al. PEI-g-chitosan, a novel gene delivery system with transfection efficiency comparable to polyethylenimine invitro and after liver administration invivo. Bioconjug Chem 2006, 17:152-158.
37. Suganuma T., Ino K., Shibata K., Kajiyama H., Nagasaka T., Mizutani S., et al. Functional expression of the angiotensin II type1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005, 11:2686-2694.
38. Issa M.M., Köping-Höggård M., Tømmeraas K., Vårum K.M., Christensen B.E., Strand S.P., et al. Targeted gene delivery with trisaccharide-substituted chitosan oligomers invitro and after lung administration invivo. JControl Release 2006, 115:103-112.
39. Kichler A., Leborgne C., März J., Danos O., Bechinger B. Histidine-rich amphipathic peptide antibiotics promote efficient delivery of DNA into mammalian cells. Proc Natl Acad Sci U S A 2003, 100:1564-1568.
40. Godbey W., Wu K.K., Mikos A.G. Tracking the intracellular path of poly (ethylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sci U S A 1999, 96:5177-5181.
41. Kosugi M., Miyajima A., Kikuchi E., Horiguchi Y., Murai M. Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin Cancer Res 2006, 12:2888-2893.
42. Amaya K., Ohta T., Kitagawa H., Kayahara M., Takamura H., Fujimura T., et al. Angiotensin II activates MAP kinase and NF-κB through angiotensin II type I receptor in human pancreatic cancer cells. Int J Oncol 2004, 25:849-856.
43. Anandanadesan R., Gong Q., Chipitsyna G., Witkiewicz A., Yeo C.J., Arafat H.A. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. JGastrointest Surg 2008, 12:57-66.
44. Ambs S., Bennett W., Merriam W., Ogunfusika M., Oser S., Khan M., et al. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer 1998, 78:233-239.
45. Pal S., Datta K., Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 2001, 61:6952-6957.
46. Herr D., Rodewald M., Fraser H., Hack G., Konrad R., Kreienberg R., et al. Potential role of renin-angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol 2008, 109:418-425.
47. He C., Hu Y., Yin L., Tang C., Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31:3657-3666.
48. Lesoon-Wood L.A., Kim W.H., Kleinman H.K., Weintraub B.D., Mixson A.J. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 1995, 6:395-405.